On 29 April, the European Respiratory Society (ERS) will be hosting a live webinar led by FAIR project experts to give a final update on the project, which will come to an end in June, 2026.
The FAIR project has reached another significant milestone with the start of a phase I clinical trial for a groundbreaking therapeutic intervention for respiratory infections.
FAIR had the great opportunity to present its objectives and preliminary findings in a full symposium at the European Respiratory Society (ERS) Congress in Vienna, Austria from September 7-11, 2024.
The FAIR project continues to drive innovation in respiratory infection therapies, and the recent ERS online course, “Virtual School of Nebulization of Drugs for Treatment of Respiratory Infections and Disease,” provided valuable insights into the latest advancements in nebulized drug delivery.
Flagellin aerosol therapy as an immunomodulatory adjunct to the antibiotic treatment of drug-resistant bacterial pneumonia (FAIR) will present a symposium at this year’s ERS Congress, from 7-11 September, in Vienna, Austria.